TrialRheumatology international2017

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.

Laure Weijers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.